Breaking News Instant updates and real-time market news.

TSLA

Tesla

$193.96

-2.55 (-1.30%)

14:13
10/18/16
10/18
14:13
10/18/16
14:13

Tesla makes second update to Model 3 site, says production begins mid 2017

Tesla, which saw a period of volatility earlier after updating its Model 3 website with what appeared to be new delivery estimates, has updated its site again. The currently accessible version states: "Production begins mid 2017. Delivery estimate for new reservations is mid 2018 or later." Earlier Tuesday, the site stated: "Production begins late 2017. Delivery estimate for new reservations is mid 2018 or later." In an archived version of the website as it appeared October 16, Tesla stated only: "Deliveries begin late 2017." Reference Link

TSLA Tesla
$193.96

-2.55 (-1.30%)

10/06/16
GSCO
10/06/16
DOWNGRADE
GSCO
Neutral
Tesla downgraded to Neutral from Buy at Goldman
Goldman analyst David Tamberrino downgraded Tesla to Neutral and lowered his price target to $185 from $240. Tamberrino sees incremental risk to Tesla's business related to management's willingness to deploy capital for M&A, and he believes that any delay in the company's new Model 3 launch will be detrimental to shares. The analyst said there is room for downward estimate revisions as volume ramps slower and spending grows. Tamberrino's 2016 earnigns estimate of (59c) is above the Street's (93c), but estimates for 2017 through 2019 are on average 48% below consensus.
10/06/16
GSCO
10/06/16
NO CHANGE
GSCO
Autos and Autos Parts sector downgraded to Cautious from Neutral at Goldman
Goldman analyst David Tamberrino downgraded the Autos and Auto Parts sector to Cautious from Neutral saying the US Auto cycle peaked in 2015 and is being held up by increasing OEM incentives. The analyst said OEM earnings will decline in 2017/2018 as negative pricing and lower production pressure North American results, but expects suppliers' earnings to hold up longer. The analyst sees upside to Delphi (DLPH) and Harman (HAR) given exposure to secular growth areas and upside to Goodyear Tire (GT) given secular HVA tire growth. Tamberrino downgraded Lear (LEA) to Sell citing elevated expectations and valuation, cut BorgWarner (BWA) to Neutral on valuation, downgraded Tesla (TSLA) to Neutral on execution risk and capital deployment, and upgraded AutoNation (AN) to Neutral given a more defensive business.
10/06/16
10/06/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Neutral from Buy at Goldman with analyst David Tamberrino saying he sees incremental risk to Tesla's business related to management's willingness to deploy capital for M&A, and he believes that any delay in the company's new Model 3 launch will be detrimental to shares. 2. JPMorgan (JPM) downgraded to Hold from Buy at Sandler O'Neill with analyst Jeffery Harte citing relative share outperformance. 3. Abercrombie & Fitch (ANF) downgraded to Sector Weight from Overweight at KeyBanc with analyst Jessica Schmidt saying the elevated promotions add to other headwinds, including the fact that the teen space is "overstored" and faces soft consumer demand and weak tourism. 4. American Express (AXP) downgraded to Reduce from Neutral at Nomura with analyst Bill Carcache saying the combination of weaker than expected revenues and higher than expected expenses will weigh on the shares. 5. Lowe's (LOW) downgraded to Neutral from Buy at Cleveland Research. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/13/16
OPCO
10/13/16
NO CHANGE
OPCO
Perform
Likelihood of Tesla, SolarCity deal closing has increased, says Oppenheimer
With Tesla (TSLA) setting the shareholder vote on November 17 for the SolarCity (SCTY) acquisition and detailing board activity at both companies in its latest filing, Oppenheimer analyst Colin Rusch believes the likelihood of the deal closing has increased. The analyst expects investors to begin to refocus on the evolution of product offerings along with capital plans and margin performance, and sees a significantly scaled-back SolarCity given staff cuts and voluntary departures. Oppenheimer has a Perform rating on Tesla's shares.

TODAY'S FREE FLY STORIES

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

, BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

17:46
04/23/17
04/23
17:46
04/23/17
17:46
Earnings
C.R. Bard raises FY17 adjusted EPS to $11.65-$11.90 from $11.45-$11.75 »

EPS consensus $11.64.…

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

, BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

17:43
04/23/17
04/23
17:43
04/23/17
17:43
Earnings
C.R. Bard sees Q2 adjusted EPS $2.75-$2.85, consensus $2.87 »

Sees Q2 revenue growth…

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

, BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

17:41
04/23/17
04/23
17:41
04/23/17
17:41
Earnings
C.R. Bard reports Q1 adjusted EPS $2.87, consensus $2.65 »

Reports Q1 revenue…

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:38
04/23/17
04/23
17:38
04/23/17
17:38
Hot Stocks
Becton Dickinson names Polen as president, says will lead Bard segment »

BD (BDX) announced the…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

HCMLY

LafargeHolcim

$11.56

-0.1 (-0.86%)

17:32
04/23/17
04/23
17:32
04/23/17
17:32
Periodicals
LafargeHolcim CEO set to step down, FT reports »

LafargeHolcim CEO Eric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:30
04/23/17
04/23
17:30
04/23/17
17:30
Hot Stocks
Becton Dickinson outlines strategic highlights of C.R. Bard acquisition »

Expanding on the…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

KLRE

KLR Energy Acquisition

$10.40

-0.02 (-0.19%)

17:29
04/23/17
04/23
17:29
04/23/17
17:29
Conference/Events
KLR Energy Acquisition to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:23
04/23/17
04/23
17:23
04/23/17
17:23
Hot Stocks
BD sees forming third business segment, says Bard CEO to join board »

Commenting on its…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:20
04/23/17
04/23
17:20
04/23/17
17:20
Hot Stocks
BD sees high single-digit EPS accretion in FY19 »

"This financially…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:18
04/23/17
04/23
17:18
04/23/17
17:18
Hot Stocks
Becton Dickinson says expects to continue buyback suspension »

"BD expects to…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:16
04/23/17
04/23
17:16
04/23/17
17:16
Hot Stocks
Becton Dickinson to acquire C.R. Bard in $24B cash and stock deal »

BD (BDX) and C. R. Bard…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:10
04/23/17
04/23
17:10
04/23/17
17:10
Hot Stocks
Breaking Hot Stocks news story on Becton Dickinson, C.R. Bard »

Becton Dickinson to…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

CS

Credit Suisse

$14.45

-0.09 (-0.62%)

17:07
04/23/17
04/23
17:07
04/23/17
17:07
Periodicals
Credit Suisse to determine capital raise plan after annual meeting, Reuters says »

Credit Suisse will make a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$142.27

-0.17 (-0.12%)

17:04
04/23/17
04/23
17:04
04/23/17
17:04
Periodicals
Uber CEO ordered iPhone tracking, was scolded by Tim Cook, NYT says »

Beginning in 2014, ride…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

AVID

Avid Technology

$5.11

0.19 (3.86%)

, MSFT

Microsoft

$66.40

0.9 (1.37%)

16:30
04/23/17
04/23
16:30
04/23/17
16:30
Hot Stocks
Avid announces strategic cloud alliance with Microsoft »

Avid (AVID) announced it…

AVID

Avid Technology

$5.11

0.19 (3.86%)

MSFT

Microsoft

$66.40

0.9 (1.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 09

    May

  • 09

    May

15:44
04/23/17
04/23
15:44
04/23/17
15:44
Conference/Events
Wolfe Research utilities analyst holds an analyst/industry conference call »

Utilities Analyst…

OA

Orbital ATK

$97.28

-0.65 (-0.66%)

15:32
04/23/17
04/23
15:32
04/23/17
15:32
Hot Stocks
Breaking Hot Stocks news story on Orbital ATK »

Orbital ATK says Cygnus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRV

ContraVir Pharmaceuticals

$1.41

-0.09 (-6.00%)

15:30
04/23/17
04/23
15:30
04/23/17
15:30
Hot Stocks
ContraVir presents data on hepatitis B candidates TXL, CRV431 »

ContraVir Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASPS

Altisource

$24.05

-1.39 (-5.46%)

, NRZ

New Residential

$16.34

-0.05 (-0.31%)

15:30
04/23/17
04/23
15:30
04/23/17
15:30
Conference/Events
Piper Jaffray specialty finance analyst holds analyst/industry conference call »

Regional Banks &…

ASPS

Altisource

$24.05

-1.39 (-5.46%)

NRZ

New Residential

$16.34

-0.05 (-0.31%)

OCN

Ocwen

$2.42

-0.07 (-2.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 03

    May

  • 24

    May

MRK

Merck

$61.89

-0.66 (-1.06%)

15:27
04/23/17
04/23
15:27
04/23/17
15:27
Hot Stocks
Merck reports new Phase 2 MK-3682B data »

Merck announced the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 07

    May

  • 10

    May

  • 27

    May

  • 09

    Jun

  • 14

    Jun

ABUS

Arbutus Biopharma

15:10
04/23/17
04/23
15:10
04/23/17
15:10
Hot Stocks
Arbutus reports ARB-1467 study data, plans additional trial in 2H »

Arbutus Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 26

    Apr

ACHN

Achillion

$3.64

-0.02 (-0.55%)

, JNJ

Johnson & Johnson

$121.76

-0.11 (-0.09%)

15:05
04/23/17
04/23
15:05
04/23/17
15:05
Hot Stocks
Achillion reports updated data from Phase 2 JNJ-4178 study »

Achillion Pharmaceuticals…

ACHN

Achillion

$3.64

-0.02 (-0.55%)

JNJ

Johnson & Johnson

$121.76

-0.11 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 06

    Jun

BMY

Bristol-Myers

$53.48

0.04 (0.07%)

14:59
04/23/17
04/23
14:59
04/23/17
14:59
Hot Stocks
Bristol-Myers says '036 NASH study meets primary endpoint »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 03

    May

  • 06

    Jun

14:52
04/23/17
04/23
14:52
04/23/17
14:52
General news
Breaking General news story  »

Fillon concedes as Le…

ALBO

Albireo Pharma

$20.66

-0.26 (-1.24%)

14:45
04/23/17
04/23
14:45
04/23/17
14:45
Hot Stocks
Albireo Pharma reports 'promising' A4250 data, sees Phase 3 trial start in 2H »

Albireo Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.